Tirzepatide activates GIP and GLP-1 receptors to help regulate blood glucose and food intake. Mounjaro and Zepbound have different treatment indications, while provider discussions often focus on finding a useful maintenance dose with manageable side effects.
Research focus: Appetite, body weight and blood-glucose control.
Choose a compound to open its research, documentation and calculator.
Mounjaro and Zepbound: approval applies to the named products and indications.
Official source ↗Elimination half-life after subcutaneous administration.
Half-life describes concentration falling by half. It does not set a dosing interval, a storage period or a drug-test detection window.
Kinetics source ↗Approved injections are supplied as solutions; do not add diluent. Tablets are not mixed. A separately supplied powder requires its own formulation documentation.
Bacteriostatic water contains a preservative; plain sterile water does not. Preservative presence does not by itself establish compatibility or a mixed medicine’s usable period.
Preparation source ↗The label instructions below apply to the named prescription products and their indications. A matching peptide name on another vial does not establish an equivalent formulation.
Check that a source concerns the same molecule, formulation, route and population. A study of cells, animals or a different product cannot confirm the contents of a vial.
Human clinical trials and US product labels, alongside labeled provider perspectives.
Learn to read a study →Each entry keeps one schedule’s amount, frequency and cycle together. Community references, individual reports, clinical trials and prescription products describe different kinds of use. A missing duration or break stays marked as not reported.
Amounts describe mass in mg or mcg. Syringe units describe volume and depend on concentration. A cycle break is different from days off within a week.
Choose an option to explore its amounts, timing and cycle.
| When | Amount & frequency |
|---|---|
| Weeks 1–4 | 2.5 mg once weekly |
| Week 5 onward | 5 mg once weekly |
| Further increase, if needed | +2.5 mg after ≥4 weeks on the current dose |
| Weight-management maintenance | 5, 10 or 15 mg once weekly; 15 mg maximum |
7.5 and 12.5 mg are intermediate strengths. For the sleep-apnea indication, maintenance is 10 or 15 mg weekly.
| When | Amount & frequency |
|---|---|
| Initial amount | 2.5 mg once weekly |
| If more glucose control is needed | +2.5 mg after ≥4 weeks on the current dose |
| Adult ceiling | 15 mg once weekly |
Adult product instructions; pediatric instructions differ.
| When | Amount & frequency |
|---|---|
| Month 1 | 2 mg once weekly |
| Month 2 | 4.5 mg once weekly |
| Month 3 · planned | 7 mg once weekly |
A reported plan with a future third stage, separate from the prescription-product schedules.
7.5 mg total over seven days in this individual account.
Community identifies source origin. It does not certify independent funding, medical credentials or the strength of a claim. Source types distinguish published reports, professional explanations and public discussions.
Explore reports, explanations and discussions from medical practices, researchers, suppliers and community members. The badges identify the source’s origin and evidence type.
How to read these source labels →This explainer is not an original trial or a survey of community schedules.
Source relationship: Commercial telehealth and weight-management provider.
Ro discusses choosing maintenance according to response and tolerability, including continuing an effective treatment dose long term.
Provider perspective · commercial care service
A peptide name and vial mass cannot determine a compatible diluent, powder displacement, storage temperature or discard date. Follow the exact product’s instructions and your pharmacist’s directions.
The injection guide concerns clinician-prescribed subcutaneous medicines; it does not establish that a research-labeled material can be injected.
Start with the formulation: dry powder, prepared solution, pen, tablet and topical product can have different instructions.
Approved tirzepatide presentations include pens and vials. Single-dose presentations use 0.5 mL per dose; multi-dose vials and KwikPens use 0.6 mL per dose in the reviewed labels. Follow the instructions for the dispensed presentation.
A prescribed compounded vial has its own concentration and handling directions. Confirm the amount in mg, concentration in mg/mL and corresponding mL with the pharmacy. Branded ready-to-use products are not reconstitution recipes for research powder.
Product presentations and handling ↗General health habits and consistent observations help you assess changes. They are not evidence that a peptide’s effects will be amplified.
Choose activity that fits your health and ability. Aerobic movement and muscle-strengthening work are part of general adult activity guidance.
CDC · adult activity ↗Use a regular sleep/wake schedule and note changes in sleep quality alongside symptoms or training.
CDC · sleep habits ↗What to record: Track food intake, appetite, activity and tolerability together. Appetite control should still leave room for adequate meals; review persistent eating difficulties with the treating clinician.
Check dates are editorial references, not a medical review certificate. Labels and evidence can change; consult the linked current document.
The labels carry a thyroid C-cell tumor boxed warning, with unknown human risk. MTC history, MEN 2 and serious hypersensitivity are contraindications. Gastrointestinal effects, pancreatitis, dehydration and interactions with glucose-lowering medicines also need review.
Full warnings and interactions ↗Ro describes maintenance as a dose chosen with the prescriber according to response and tolerability. Some people continue an effective treatment amount long term; “maintenance” does not necessarily mean reducing it after reaching a weight goal.
That supports a practical conversation about benefits, side effects and adequate nutrition. It does not establish a universal four-week pause, automatic step-down or a schedule based only on appetite. Extending intervals to 8–10 days or using “microdoses” falls outside the labeled weekly plan.
Read the provider’s full discussion ↗The label allows taking it within four days (96 hours). After that, skip it and resume the usual weekly day.
Missed-dose instructions ↗Leave at least three days (72 hours) between doses when changing the day. This exception does not create an every-three-days regimen.
Weekly-day instructions ↗Subcutaneous, with or without food, at any time of day. Rotate abdomen or thigh sites; another person can inject the back of the upper arm.
Administration instructions ↗Selected studies and clinical reports, with the question, context and limitations close at hand.
How did tirzepatide compare with placebo for weight reduction in adults with obesity or overweight and a weight-related complication?
Opening values and worked examples illustrate arithmetic; they are not preparation instructions or recommended amounts. Selecting a compound labels the calculation and does not supply a dose or powder-volume correction.
Enter the documented vial mass, preparation information and target amount to see how mass and volume connect.
20 mg in an assumed final 1 mL gives 20 mg/mL. An entered 1 mg corresponds to 0.05 mL, or 5 U-100 units, with 20 theoretical portions before losses.
Estimate · assumes 1 mL added = total volume
1,000 mcg
Theoretical · before losses
0.2 mL
After 5 full doses
Illustration only · calculated value, without rounding
Saved calculations stay on this device.
Concentration = mass ÷ final volume
5 mg ÷ 1 mL = 5 mg/mLVolume = target mass ÷ concentration
1 mg ÷ 5 mg/mL = 0.2 mLU-100 markings = volume × 100
0.2 mL × 100 = 20 unitsComplete portions = floor(vial mass ÷ amount per portion).
Displayed numbers are rounded for readability; the calculation uses unrounded values.
Already have the concentration? Find the matching mL and U-100 syringe reading.
Need the concentration first? Use the Reconstitution tab.
5units
0.05 mL · 0.25 mg
0.25 mg ÷ 5 mg/mL = 0.05 mLU-100 units = mL × 100Example inputs are editable. The reading is calculated without rounding to a physical graduation.
Convert mass or liquid volume. U-100 markings always refer to a 100-units-per-mL scale.
1,000mcg
For mass → syringe volume, switch to Dosage and enter a concentration.